The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting continued M&A activity in the biotech sector, drugmaker Zymeworks announced on Monday it will acquire Theravance Biopharma in a $929 million deal. The acquisition aims to bolster Zymeworks' pipeline by leveraging Theravance's therapeutic assets, according to reports.
The deal comes amid a wave of mid-cap mergers in the pharmaceutical industry, as companies seek to combine resources and accelerate drug development. The transaction is expected to undergo customary regulatory reviews before closing.
Sign in to access this content
Sign InInvestors will focus on the regulatory timeline and Zymeworks' ability to successfully integrate Theravance's assets. Markets will also monitor the stocks of both companies when trading resumes, though specific financing details remain undisclosed.